A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer

Inclusion Criteria: * Adult females over age 18 with life expectancy of at least 3 months * Histologically or cytologically confirmed locally advanced or metastatic breast cancer * One and only one prior chemotherapy regimen (no prior docetaxel) * Measurable disease (at least one target lesion)at least 2 cm in longest diameter (1 cm by spiral CT) * Adequate hematologic, renal, and hepatic function; Exclusion Criteria: * Known history of bleeding diathesis or coagulopathy * Any current evidence of clinically significant bleeding * Any history of thromboembolic events * Concurrent hormone therapy * Prior immunotherapy or radiotherapy to an area of measurable disease unless disease has recurred after radiotherapy